Article Details

Iovance downgraded at Goldman Sachs citing concerns on lead asset - Seeking Alpha

Retrieved on: 2022-12-09 16:08:06

Tags for this article:

Click the tags to see associated articles and topics

Iovance downgraded at Goldman Sachs citing concerns on lead asset - Seeking Alpha. View article details on hiswai:

Excerpt

Shares of Iovance Biotherapeutics (IOVA) fell in the morning hours Friday after Goldman Sachs downgraded the clinical-stage biotech to Neutral ...

Article found on: seekingalpha.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up